SouthState Corp’s Alnylam Pharmaceuticals ALNY Stock Holding History

SouthState Corp’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.23K	Sell	5 -6	-55%	-$1.53K	﹤0.01%	1086
2026 Q2	$3.31K	Sell	11 -2	-15%	-$603	﹤0.01%	861
2026 Q1	$4.3K	Sell	13 -1	-7%	-$340	﹤0.01%	778
2025 Q4	$5.57K	Sell	14 -6	-30%	-$2.66K	﹤0.01%	783
2025 Q3	$9.12K	Sell	20 -6	-23%	-$2.44K	﹤0.01%	676
2025 Q2	$8.48K	Buy	26 +5	+24%	+$1.38K	﹤0.01%	813
2025 Q1	$5.67K	Buy	+21	New	+$5.4K	﹤0.01%	964
2024 Q2	–	Sell	-6	Closed	-$897	–	641
2024 Q1	$897	Buy	+6	New	+$1K	﹤0.01%	651

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

SouthState Corp's ALNY Position: Q3 2026 in Review

SouthState Corp reduced its Alnylam Pharmaceuticals (ALNY) stake by 55% in Q3 2026, selling an estimated $1.53K and leaving 5 shares worth $1.23K. The position accounts for ﹤0.01% of the portfolio, ranked #1086.

SouthState Corp first reported a position in ALNY in Q1 2024 and has held it in 8 quarters since. The position peaked at $9.12K in Q3 2025. 403 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

SouthState Corp held 5 shares of Alnylam Pharmaceuticals worth $1.23K as of Q3 2026.
SouthState Corp sold 6 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $1.53K.
Alnylam Pharmaceuticals made up ﹤0.01% of SouthState Corp's portfolio in Q3 2026, its #1086 holding.
SouthState Corp first reported a position in Alnylam Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
SouthState Corp's Alnylam Pharmaceuticals position peaked at $9.12K in Q3 2025.
403 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on SouthState Corp's 13F filing for Q3 2026, filed 9 Nov 2026.